All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Pulmonary sarcoidosis is characterised by parenchymal granulomas of unknown cause(s) \[[@pone.0161669.ref001], [@pone.0161669.ref002]\]. A typically observed immunological feature is a helper T cell type 1 (Th1) polarisation of chronic inflammation with elevated secretion of interleukin (IL)-2, IL-8, IL-12, interferon (IFN) gamma and tumour necrosis factor (TNF) alpha at sites of this disease. A contribution of Th2 cytokine profile (e.g. IL-4 and IL-6) is hypothesized in advanced sarcoidosis\[[@pone.0161669.ref001], [@pone.0161669.ref003]\]. Furthermore, there is an increasing biosynthesis of pro-fibrogenic factors (e.g. tumour growth factor (TGF) beta) and proteolytic enzymes (e.g. matrix metalloproteinases (MMP)) during sarcoidosis progression \[[@pone.0161669.ref001], [@pone.0161669.ref002], [@pone.0161669.ref004]--[@pone.0161669.ref006]\].

Besides sarcoidosis\[[@pone.0161669.ref004], [@pone.0161669.ref005]\], other respiratory diseases, including chronic obstructive pulmonary disease (COPD), asthma, and idiopathic interstitial pneumonia (IIPs), are associated with a similar elevation of some pro-inflammatory factors and MMPs (e.g.MMP-9) \[[@pone.0161669.ref007]--[@pone.0161669.ref009]\].

Inflammation, polarization of Th immune responses and expression of the corresponding pro-inflammatory factors are modulated at post-transcriptional level\[[@pone.0161669.ref010]--[@pone.0161669.ref013]\]. In this process, two components are of great importance for the post-transcriptional regulation: RNA-binding proteins (RBPs) and microRNAs. Contrary to microRNA's specific binding sites, RBPs bind AU-rich elements (ARE) that relatively commonly exists at 3' end of mRNA, encoding for several cytokines, transcriptional factors and MMPs\[[@pone.0161669.ref010]--[@pone.0161669.ref012]\]. Subsequently, the RBP-ARE interactions modulate the fate of the targeted mRNA. Among various RBPs, HuR (alias ELAVL1) usually stabilizes the targeted mRNA while the inhibitory RBPs such as AUF1 (alias HNRNPD) and TIA/TIAR complex act against the stability and translation, respectively \[[@pone.0161669.ref010]--[@pone.0161669.ref012]\].

In particular, HuR stabilizes Th2 transcription factor GATA3 mRNA as well as Th2 specific cytokine mRNAs of IL-4 and IL-13 and thus promotes a polarisation of immune response to Th2 \[[@pone.0161669.ref014]\]. Another RBP called AUF1 promotes the mRNA destabilization of IL-6, but can also support mRNA expression under specific conditions\[[@pone.0161669.ref015], [@pone.0161669.ref016]\]. The function of the active RBPs is usually associated with their cytoplasmic accumulation, but they also shuttle to nucleus where they can first meet their target mRNA sequence\[[@pone.0161669.ref017]\]. In the context of sub-cellular localisation, another RBP called NCL (alias nucleolin) has an unique property as it is additionally present on the cellular surface of macrophages where it mediates phagocytosis of apoptotic cells\[[@pone.0161669.ref018]\]. Of these RBPs, NCL, HuR and AUF1 have all been reported to affect MMP-9 expression\[[@pone.0161669.ref019]--[@pone.0161669.ref021]\]

A lot of potential targets of the RBPs, including MMP-9, have already been reported to be dysregulated in sarcoidosis \[[@pone.0161669.ref001], [@pone.0161669.ref002], [@pone.0161669.ref004], [@pone.0161669.ref005], [@pone.0161669.ref010], [@pone.0161669.ref019]--[@pone.0161669.ref022]\]. To our knowledge, no clinical study has yet addressed the *in vivo* expression of RBPs in pulmonary sarcoidosis or other non-malignant pulmonary pathologies. Two inhibitors of MMP-9 termed RECK (reversion-inducing-cysteine-rich protein with kazal motifs) and PTEN (phosphatase and tensin homolog) also have AU-rich elements ([www.AREsite.com](http://www.AREsite.com)) \[[@pone.0161669.ref023]--[@pone.0161669.ref025]\] but limited information about their expression exists in lung diseases.

We, therefore, decided to evaluate *in vivo* bronchoalveolar (BA) expression of six RBPs (AUF1, HuR, NCL, TIA, TIAR and PCBP2) and of two possible targets of RBPs (MMP-9 inhibitor RECK and PTEN) in our patients with pulmonary sarcoidosis and compare it with that in four control groups including healthy subjects, obstructive (COPD and asthma) and non-obstructive pathologies (IIPs).

Methods {#sec006}
=======

Subjects {#sec007}
--------

Bronchoalveolar lavage (BAL) was performed according to our standard protocol (Petrek et al 1993) from 50 patients with pulmonary sarcoidosis (male/female 25/25; mean age 44 years, min-max 21--77 years), 23 healthy control subjects (17/6; 43, 19--78), 30 COPD patients (18/12; 64, 40--84 years), 19 asthmatic patients (5/14; 45, 20--83) and 19 IIPs patients (6/13; 57, 33--80) ([S1 File](#pone.0161669.s001){ref-type="supplementary-material"}). BA cellular profiles of all study groups are provided in [S1 Table](#pone.0161669.s002){ref-type="supplementary-material"}. In addition, 9 patients with pulmonary sarcoidosis (men/women 5/4; mean age 54, min-max 41--80) and 6 healthy controls (1/5; mean age 45, min-max 35--59) provided peripheral blood samples for the analyses by flow cytometry.

Diagnosis of pulmonary sarcoidosis was made according to the criteria of ATS/ERS/WASOG International Consensus Statement\[[@pone.0161669.ref001]\]. The BAL samples were obtained from Czech pulmonary sarcoid patients without Löfgren's syndrome (n = 50) who were classified with CXR (chest X ray) stage I (n = 25) and CXR stage II (n = 25). Blood samples were obtained from Swedish pulmonary sarcoid patients with/without Löfgren's syndrome (n = 2/7) who were classified with CXR stage I (n = 1), II (n = 3), II-III (n = 1), III (n = 2) and IV (n = 2). COPD and asthma were defined according to the criteria of the Global initiative for chronic Obstructive Lung Disease (GOLD) \[[@pone.0161669.ref026]\]and Global INitiative for Astma (GINA)\[[@pone.0161669.ref027]\], respectively. All COPD patients had mild or moderate airway obstruction defined as an FEV1/FVC (Forced Expiratory Volume in one second / Forced Vital Capacity) ratio \<0.7 and FEV1% predicted 50--79%. We futher enrolled the patients with IIPs based on typical clinical and radiological features together with the histopathological confirmation on surgical lung biopsy \[[@pone.0161669.ref028]--[@pone.0161669.ref030]\].

All samples of BAL were obtained in Department of Respiratory Medicine, Palacký University Hospital in Olomouc, the Czech Republic. Blood sampling (from different patients) was performed at the Karolinska Institutet in Stockholm, Sweden. All Czech and Swedish patients gave their informed consent to participate in the study, which was approved by the local Ethical committees of the Medical Faculty PU & University Hospital (Olomouc, the Czech Republic) and Karolinska Institutet (Stockholm, Sweden).

BA cells processing, RNA isolation and reverse transcription {#sec008}
------------------------------------------------------------

BA cells were separated from the fluid by centrifugation as described previously \[[@pone.0161669.ref031]\]. The total RNA was isolated with High Pure miRNA Kit (Roche, Germany). Reverse transcription was performed by Transcriptor First Strand cDNA Synthesis Kit (Roche, Germany).

Gene expression measurements by real-time RT-PCR {#sec009}
------------------------------------------------

RotorGene3000 system (Corbett Research, Sydney, Australia) was used to assess relative expression. RT-PCR reaction conditions and a reference gene are described elsewhere \[[@pone.0161669.ref032]\]. Full names of here measured genes with their general effect on inflammation, the corresponding primer sequences, and probes for the investigated genes are listed in [S2 Table](#pone.0161669.s003){ref-type="supplementary-material"}.

PBMCs processing and flow cytometry {#sec010}
-----------------------------------

Heparinized whole blood was kept at room temperature. Peripheral blood mononuclear cells (PBMCs) were separated by Ficoll-gradient (Ficoll Paque PLUS, GE Healthcare, Uppsala, Sweden) and washed twice with cell wash (PBS, 0.5%BSA and 0.02%NaN~3~). From each sample, 0.5×10^6^ PBMCs were fixed by Fixation/Permeabilization Concentrate and Diluent (eBioscience), permeabilized by Permeabilization Buffer (eBioscience) and stained for surface proteins using the following antibodies; CD3-Pacific Blue (BD Pharmingen), anti CD4-APC-H7 (BD Pharmingen) and CD8-AmCyan (BD Pharmingen). For intracellular staining of cytoplasmic and nuclear proteins the following antibodies were used: polyclonal rabbit IgG anti-AUF1-APC (LifeSpan BioSciences), monoclonal mouse IgG1 kappa anti-HuR-APC (LifeSpan BioSciences), APC mouse IgG1 kappa isotype control (BD Pharmingen) and APC rabbit IgG isotype control (Santa Cruz biotechnology). Results are expressed as mean fluorescence intensity (MFI) minus background provided by the isotype-matched negative control antibodies. Samples were run on an eight-colour FACSCanto II flow cytometer (Becton Dickinson). Data were analysed with Flowjo 10, Treestar.

Statistics {#sec011}
----------

Mann-Whitney U-test was used to detect possible effect of cigarette smoking and aging in each disease (pulmonary S, COPD and asthma) and healthy control group. Kruskal-Wallis test with Dunn's multiple comparison tested differences in the expression of the investigated genes among sarcoidosis, healthy controls and three patient control groups with COPD, asthma and IIPs (GraphPad Prism; GraphPad, La Jolla, CA USA). The primary analysis of Kruskal-Wallis test with Dunn's multiple comparison included all recruited patients and the subsequent sub-analysis took into consideration smoking status. Correlations were examined using Spearman's rank correlation coefficient (SPSS 12.0 for Windows; SPSS, Chicago, IL, USA). A *p* value \< 0.05 was considered to be significant.

Results {#sec012}
=======

Bronchoalveolar (BA) expression of RBP mRNA in pulmonary sarcoidosis compared to healthy controls {#sec013}
-------------------------------------------------------------------------------------------------

Dunn\'s Multiple Comparison Test of five investigated groups including all recruited patients regardless of smoking status showed significantly decreased relative expressions of AUF1 (*p*\<0.001), HuR (*p*\<0.001), TIA (*p*\<0.001), TIAR (*p*\<0.05) and NCL (*p*\<0.001) and RECK (*p*\<0.001) in BA cells from the patients with pulmonary sarcoidosis compared to those in healthy controls ([Fig 1](#pone.0161669.g001){ref-type="fig"} and [S3 Table](#pone.0161669.s004){ref-type="supplementary-material"}). The relative expression of PTEN did not differ in the patients with pulmonary sarcoidosis compared to that in healthy controls. There was no difference in neither RBPs nor the inhibitors of MMPs between CXR (chest X ray) stage I and stage II (for all *p*\>0.05). The subsequent sub-analysis of never smokers showed that AUF1 (*p*\<0.001), TIA (*p*\<0.001), NCL (*p*\<0.01) and RECK (*p*\<0.05) remained to be down-regulated in sarcoidosis compared to healthy controls ([Fig 1](#pone.0161669.g001){ref-type="fig"} and [S3 Table](#pone.0161669.s004){ref-type="supplementary-material"}).

![The relative mRNA expression of RNA-binding proteins (RBPs) and an inhibitor of proteolytic activity RECK in pulmonary sarcoidosis (S) in comparison with healthy controls (C) and patients with chronic obstructive pulmonary disease (COPD), asthma and idiopathic interstitial pneumonia (IIPs).](pone.0161669.g001){#pone.0161669.g001}

Bronchoalveolar (BA) expression of RBP mRNA in pulmonary sarcoidosis compared to other control groups with COPD, asthma and IIPs {#sec014}
--------------------------------------------------------------------------------------------------------------------------------

Regardless of smoking status, a decreased expression of AUF1 (*p*~*COPD*~\<0.001, *p*~*asthma*~\<0.01), TIA (*p*~*COPD*~\<0.001, *p*~*asthma*~\<0.001) and NCL (*p*~*COPD*~\<0.001, *p*~*asthma*~\<0.001) was observed in patients with sarcoidosis compared to both obstructive pathologies (COPD and asthma; [Fig 1](#pone.0161669.g001){ref-type="fig"} and [S3 Table](#pone.0161669.s004){ref-type="supplementary-material"}). The subsequent sub-analysis of never smokers showed the decreased expression of TIA (*p*~*COPD*~\<0.05, *p*~*asthma*~\<0.05) in sarcoidosis patients compared to both obstructive pathologies (COPD and asthma) and additionally NCL (*p*~*COPD*~\<0.05) compared to COPD patients ([Fig 1](#pone.0161669.g001){ref-type="fig"} and [S3 Table](#pone.0161669.s004){ref-type="supplementary-material"}).

Bronchoalveolar (BA) expression of RBP mRNA in other pulmonary diseases {#sec015}
-----------------------------------------------------------------------

Comparisons among 4 control groups of healthy controls and disease controls (COPD, asthma and IIPs) are summarised in supplement and [S4 Table](#pone.0161669.s005){ref-type="supplementary-material"}. Briefly, AUF1 (*p*\<0.001), TIA (*p*\<0.001), NCL (*p*\<0.001), PCBP2 (*p*\<0.001) and RECK (*p*\<0.001) were down-regulated in IIPs compared to healthy controls.

The effect of smoking and age on BA expression of RBP mRNA {#sec016}
----------------------------------------------------------

The possible effect of smoking was investigated by several analyses between never smokers and smokers ([S1 File](#pone.0161669.s001){ref-type="supplementary-material"}). The expression of RBPs and two inhibitors of proteolytic enzymes did not differ between the sub-groups of our patients with pulmonary sarcoidosis (*p*\>0.05).

Regarding age, the relative expressions did not differ between our young (*≤*45 years, n = 25) and elderly (\>45 years, n = 25) patients with pulmonary sarcoidosis (*p*\>0.05). The data on the effect of age in control groups is provided in [S1 File](#pone.0161669.s001){ref-type="supplementary-material"}.

Correlation analyses {#sec017}
--------------------

To investigate *in vivo* relationship between RBPs and the possible targets, we performed several correlation analyses between the BA mRNA expressions of RBPs and the BA mRNA expressions of genes encoding for inhibitors of MMPs with ARE. Among sarcoidosis patients, RECK decreased in parallel with decreasing expression of AUF1 (*p* = 0.002), NCL (*p* = 0.02), HuR (*p* = 0.002), TIA (*p*\<0.001) and TIAR (*p* = 0.007). There was no relationship between PTEN and RBPs in our patients with sarcoidosis.

Regarding cellular profile of BAL (bronchoalveolar lavage), the BA relative expression of PCBP2 mRNA showed negative correlations with absolute and relative numbers of lymphocytes (*p* = 0.003 and *p* = 0.003) in the patient group of pulmonary sarcoidosis. The information on other relationships between the cellular profile of BAL and mRNA expressions in all patient groups is provided in [S1 File](#pone.0161669.s001){ref-type="supplementary-material"}.

RBPs in peripheral blood mononuclear cells (PBMCs) obtained from patients with pulmonary sarcoidosis {#sec018}
----------------------------------------------------------------------------------------------------

Because the investigation of RBPs in sarcoidosis was our primary aim, two of the most extensively studied RBPs (AUF1 and HuR) were further selected for the investigation of RBP protein expression in sarcoidosis peripheral blood T lymphocytes (PBTLs). Total CD3+ as well as CD4+ and CD8+ PBTLs obtained from PBMCs of the patients with sarcoidosis displayed lower mean fluorescence intensity (MFI) of AUF1 (*p≤*0.02) and HuR (*p≤*0.03) than those from healthy controls ([Fig 2](#pone.0161669.g002){ref-type="fig"}).

![AUF1 and HuR protein expressions in CD3+, CD4+ and CD8+ T lymphocytes of peripheral blood obtained from the patients with pulmonary sarcoidosis and healthy controls.\
Legend: PBMC, peripheral blood mononuclear cells; MFI, mean fluorescence intensity. The data are expressed as whisker box plots; the box represents the 25--75th percentiles, the median is indicated by a bar across the box, the whiskers on each box represent the 10--90th percentiles.](pone.0161669.g002){#pone.0161669.g002}

Discussion {#sec019}
==========

There has been yet no information on *in vivo* expression of RNA-binding proteins (RBPs) in respiratory diseases. Taking the stringent conditions for multiple comparisons and smoking status into consideration, we observed the decreased expression of three RBPs (AUF1, TIA and NCL) in bronchoalveolar (BA) cells from our patients with pulmonary sarcoidosis compared to those from our healthy controls. Additionally, TIA was also down-regulated in both airway obstructive pathologies (COPD and asthma) but not in our patients with another diffuse lung disease, IIP. Regarding inhibitors of proteolytic enzymes being under post-transcriptional control of RBPs, lower expression of RECK was observed in BA cells in all investigated patient groups compared to healthy controls. Furthermore, several RBPs correlated with BA expression of RECK in different lung inflammatory pathologies. Although these correlations provide only an indirect proof of physical contact between RBPs and RECK, their *in vivo* relationship is likely.

The strength of our work lies within the *in vivo* assessment of clinically relevant biological material such as BA cells that are in tight contact with the lung inflammatory processes. In this study, RBPs were not affected by either cigarette smoking or age. In line with our data on smoking, Hudy et al reported that cigarette smoke extract does not induce any dysregulation of RBPs (AUF1 and HuR) in primary human bronchial epithelial cells \[[@pone.0161669.ref033]\]. In contrast to these RBPs, Glader et al. observed that *in vitro* stimulation by cigarette smoke extract reduces the expression of another RBP (TIA) \[[@pone.0161669.ref034]\]. Because of the inconsistent *in vitro* \[[@pone.0161669.ref033], [@pone.0161669.ref034]\] and our *in vivo* data on TIA, we have performed both primary analysis regardless smoking status and then the smoking status-matched case-control sub-analyses. The case-control sub-analysis of never smokers with sarcoidosis showed that the down-regulation of AUF1, TIA and NCL in our patients with sarcoidosis is independent of smoking status. By contrast, the down-regulation of HuR and TIAR in sarcoidosis did not reach significant level in the sub-analysis of never smokers. The inconsistent results between our primary analyses of all patients and our subsequent sub-analyses of never smokers suggest that the expression of HuR and TIAR could be partly affected by the smoking status but did not reach significant level because the effect of smoking is not profound.

Similar to sarcoidosis, we observed several RBPs (AUF1, TIA, NCL and addition TIAR and PCBP2) to be decreased in our patients with IIPs, but not in our patients with airway obstructive pathologies (COPD and asthma) when comparing to healthy controls. Furthermore, the expression of TIA was additionally decreased in our patients with sarcoidosis compared to those with both airway obstructive pathologies (COPD and asthma) but not compared to those with another diffuse lung disease, IIP. The comparison with two obstructive pathologies suggests that AUF1, NCL and mainly TIA are important regulation factors namely in pulmonary interstitial lung diseases.

One may argue that the observed decreased expressions of RBPs (AUF1, NCL and TIA) may not be associated with sarcoidosis but rather be an effect of the elevated sub-population of BA lymphocytes being a hallmark of pulmonary sarcoidosis. In line with this hypothesis, we observed the correlation between PCBP2 mRNA and BA lymphocyte sub-population in our patients with pulmonary sarcoidosis. In contrast to PCBP2, the mRNA expression of other RBPs and two inhibitors of MMP-9 (RECK and PTEN) did not correlate with any BA sub-population in our patients with sarcoidosis. However, we can not exclude the possibility that the sarcoidosis down-regulation of some RBP mRNAs (e.g. TIA) is primarily dependent on other BA sub-populations that were not assessed in our patients with sarcoidosis, e.g. the reduced number of BA natural killer T cells in sarcoidosis \[[@pone.0161669.ref035]\]. Future studies should, therefore, directly assess the RBPs in the particular BA sub-populations including alveolar macrophages and broad spectrum of different T lymphocytes.

To start with the investigation of cell sub-populations, we further used flow cytometry to investigate the protein expressions of AUF1 and HuR in peripheral blood T lymphocytes (PBTLs) obtained from independent group of sarcoidosis patients. The expression of AUF1 protein was consistently down-regulated in both CD4+ and CD8+ PBTLs from our patients with sarcoidosis compared to those from healthy controls. Similar to the AUF1 protein, we observed the decreased expression of HuR protein in our patients with sarcoidosis.

In the healthy lung and in leukocytes, RBPs are more highly expressed than microRNAs and even than transcription factors, possibly indicating the importance of RBPs in monitoring of lung inflammation\[[@pone.0161669.ref036]\]. At present time, however, most human studies on RBPs are restricted to malignancies. Actually, as late as the last year (2014), a complex expression of RBPs was investigated in various cancers\[[@pone.0161669.ref036]\]. A general abundance of RBPs was reported in lung carcinoma. It is in contrast with the mRNA down-regulation of AUF1, NCL and TIA in BA cells and the protein down-regulation of AUF1 and HuR in PBTL from our patients with sarcoidosis. Based on current knowledge \[[@pone.0161669.ref004], [@pone.0161669.ref005], [@pone.0161669.ref015], [@pone.0161669.ref016], [@pone.0161669.ref019]\], we can only speculate that the down-regulated expressions may support sarcoid inflammation by an insufficient degradation of mRNA encoding for cytokines (e.g. IL-6), chemokines (e.g. IL-8) and proteolytic enzymes (e.g. MMP-9). In parallel, the effect of RBPs (e.g. HuR) on the pro-inflammatory factors may be mediated by targeting mRNA encoding for transcriptional factors and second messengers in specific sub-populations of differentiated T lymphocytes\[[@pone.0161669.ref037]\]. Genome-wide measurement of stead-state mRNA in the particular sub-populations of at least circulating T lymphocytes could therefore bring new information on post-transcriptional regulation mechanisms in sarcoidosis\[[@pone.0161669.ref038]\].

RECK and PTEN with their ARE sites are also potential targets of the RBPs-mediated regulation of inflammation.

RECK protein is a cellular membrane anchored glycoprotein that inhibits both expression and proteolytic activity of MMP-9 \[[@pone.0161669.ref024]\]. The low mRNA expression of RECK in our patients with different pulmonary pathologies could therefore support the well-known increased proteolytic degradation of connective tissue in these inflammatory lung diseases \[[@pone.0161669.ref039], [@pone.0161669.ref040]\]. In addition, the low mRNA expression of RECK in our asthmatic patients is in line with a previous observation on sputum samples from asthmatic patients \[[@pone.0161669.ref041]\].

We also observed the mRNA expression of RECK to correlate with five RBPs (AUF1, HuR, NCL, TIA and PCBP2). However, the particular interaction between RECK ARE site and RBP has not been experimentally investigated so far. Our correlation analysis also provides only indirect proof of physical interaction. We must therefore mention that the *in vivo* relationship may be also mediated by other RBPs (e.g. TTP) and other regulation mechanisms\[[@pone.0161669.ref012]\]. In this context, an important aspect is that we only measured mRNA expressions of BA RBPs whose protein concentrations do not have to correlate with the expression of the putatively targeted mRNA encoding for RECK gene. Other clinical studies should therefore assess RBPs and their potential targets at protein levels. Second, post-translation phosphorylation and sub-cellular localisation of RBPs may play important role in the post-transcriptional regulation of RECK mRNA stability and its translation \[[@pone.0161669.ref012]\]. Third, other important factor of post-transcription regulation is a silencing of targeted mRNA by microRNA \[[@pone.0161669.ref012], [@pone.0161669.ref022]\].

Conclusion {#sec020}
==========

The down-regulated mRNA expressions of three RBPs (AUF1, TIA and NCL) in unseparated bronchoalveolar cells and the down-regulated protein expressions of two RBPs (AUF1 and HuR) in peripheral blood T lymphocytes were observed in our patients with pulmonary sarcoidosis. These expression data indicate down-regulated expressions of the RBPs in sarcoidosis. Further, low mRNA expression of RECK was present in our patients with pulmonary sarcoidosis, COPD and IIPs. The low expression of RECK may shift a proteinase / anti-proteinase balance to excessive proteolytic character in these diseases. Further studies are required to clarify the particular targets that are regulated by RBPs in bronchoalveolar cells in diffuse and inflammatory lung disease. The assessment of stead-state mRNA encoding for the particular targeted gene is also desirable as it may bring key information on role of RBPs in the chronic inflammation of sarcoidosis and other respiratory diseases.
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